Ethanol has paradoxical effects on the human myocardium; consumption of large amounts over a lifetime can lead to alcoholic cardiomyopathy, whereas consumption of ethanol in moderation can prevent or reduce the risk of coronary artery disease (CAD) and cardiac ischemia. In addition to the preventive effect of moderate consumption of ethanol on CAD, acute exposure to ethanol induces a direct protective effect on the myocardium. This latter mode of protection by ethanol is thought to mimic a natural form of cardioprotection, termed ischemic preconditioning. However, the cardioprotective effect of ethanol appears to have a narrow therapeutic window; ethanol exerts both negative and positive effects on the myocardium. Identifying the mediators of ethanol's effects on the heart and identifying means to selectively activate those that are cardioprotective and inhibit those that contribute to cardiac damage may enable the use of ethanol in prevention of cardiac damage during or after acute MI. The research proposal described above focuses on one scenario - the effect of acute exposure to ethanol on the response of the heart to ischemia and reperfusion. We plan to determine the role of ethanol on the activities of mitochondrial enzymes that correlate with the cardioprotective effect of ethanol (AIM 1), identify ethanol-induced PKC-selective substrates and their role in cardioprotection (AIM 2) and determine whether acute treatment with ethanol can be used as a cardioprotective agent in a large animal model of transient ischemia and reperfusion in vivo (AIM 3). Together, our studies will assess the molecular basis and potential use of ethanol as an agent to protect the heart from ischemic damage.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
5R01AA011147-10
Application #
7062541
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Brown, Ricardo A
Project Start
1996-09-30
Project End
2009-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
10
Fiscal Year
2006
Total Cost
$427,230
Indirect Cost
Name
Stanford University
Department
Biology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Sarvi, Sana; Crispin, Richard; Lu, Yuting et al. (2018) ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol 25:1456-1469.e6
Chang, Peter Mu-Hsin; Chen, Che-Hong; Yeh, Chi-Chun et al. (2018) Transcriptome analysis and prognosis of ALDH isoforms in human cancer. Sci Rep 8:2713
Joshi, Amit U; Mochly-Rosen, Daria (2018) Mortal engines: Mitochondrial bioenergetics and dysfunction in neurodegenerative diseases. Pharmacol Res 138:2-15
Kiyuna, Ligia Akemi; Albuquerque, Rudá Prestes E; Chen, Che-Hong et al. (2018) Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities. Free Radic Biol Med 129:155-168
Saiki, Julie P; Cao, Hongbin; Van Wassenhove, Lauren D et al. (2018) Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. Proc Natl Acad Sci U S A 115:6279-6284
Ueta, Cintia Bagne; Campos, Juliane Cruz; Albuquerque, Rudá Prestes E et al. (2018) Cardioprotection induced by a brief exposure to acetaldehyde: role of aldehyde dehydrogenase 2. Cardiovasc Res 114:1006-1015
Joshi, Amit U; Saw, Nay L; Vogel, Hannes et al. (2018) Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol Med 10:
Kim, Jeewon; Chen, Che-Hong; Yang, Jieying et al. (2017) Aldehyde dehydrogenase 2*2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment. J Biomed Sci 24:33
Hu, Yu-Feng; Chang, Yao-Ting; Lin, Yenn-Jiang et al. (2017) The roles of alcohol dehydrogenase in patients with atrial fibrillation. Pacing Clin Electrophysiol 40:1446-1453
Qvit, Nir; Kornfeld, Opher S; Mochly-Rosen, Daria (2017) Corrigendum: Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics. Angew Chem Int Ed Engl 56:2236

Showing the most recent 10 out of 69 publications